These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27739219)

  • 21. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.
    Alves AC; Etxebarria A; Soutar AK; Martin C; Bourbon M
    Hum Mol Genet; 2014 Apr; 23(7):1817-28. PubMed ID: 24234650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia.
    Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
    Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.
    Huijgen R; Sjouke B; Vis K; de Randamie JS; Defesche JC; Kastelein JJ; Hovingh GK; Fouchier SW
    Hum Mutat; 2012 Feb; 33(2):448-55. PubMed ID: 22095935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
    Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
    Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Baila-Rueda L; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Mateo-Gallego R; Lamiquiz-Moneo I; de Castro-Orós I; Cenarro A; Civeira F
    Atherosclerosis; 2016 Mar; 246():202-7. PubMed ID: 26802983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
    Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR
    Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The study of familial hypercholesterolemia in Italy: A narrative review.
    Bertolini S; Pisciotta L; Fasano T; Rabacchi C; Calandra S
    Atheroscler Suppl; 2017 Oct; 29():1-10. PubMed ID: 28965614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Martin R; Latten M; Hart P; Murray H; Bailie DA; Crockard M; Lamont J; Fitzgerald P; Graham CA
    Atherosclerosis; 2016 Nov; 254():8-13. PubMed ID: 27680772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
    Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 inhibitors.
    Gencer B; Lambert G; Mach F
    Swiss Med Wkly; 2015; 145():w14094. PubMed ID: 25856746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.
    Hopkins PN; Defesche J; Fouchier SW; Bruckert E; Luc G; Cariou B; Sjouke B; Leren TP; Harada-Shiba M; Mabuchi H; Rabès JP; Carrié A; van Heyningen C; Carreau V; Farnier M; Teoh YP; Bourbon M; Kawashiri MA; Nohara A; Soran H; Marais AD; Tada H; Abifadel M; Boileau C; Chanu B; Katsuda S; Kishimoto I; Lambert G; Makino H; Miyamoto Y; Pichelin M; Yagi K; Yamagishi M; Zair Y; Mellis S; Yancopoulos GD; Stahl N; Mendoza J; Du Y; Hamon S; Krempf M; Swergold GD
    Circ Cardiovasc Genet; 2015 Dec; 8(6):823-31. PubMed ID: 26374825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of familial hypercholesterolemia in Spain.
    Palacios L; Grandoso L; Cuevas N; Olano-Martín E; Martinez A; Tejedor D; Stef M
    Atherosclerosis; 2012 Mar; 221(1):137-42. PubMed ID: 22244043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
    Pirillo A; Garlaschelli K; Arca M; Averna M; Bertolini S; Calandra S; Tarugi P; Catapano AL;
    Atheroscler Suppl; 2017 Oct; 29():17-24. PubMed ID: 28965616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.